Back to Search Start Over

SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence.

Authors :
Han Y
Yang L
Kim TW
Nair MS
Harschnitz O
Wang P
Zhu J
Koo SY
Tang X
Lacko LA
Chandar V
Bram Y
Zhang T
Zhang W
He F
Caicedo J
Huang Y
Evans T
van der Valk P
Titulaer MJ
Spoor JKH
Furler RL
Canoll P
Goldman JE
Przedborski S
Schwartz RE
Ho DD
Studer L
Chen S
Source :
Research square [Res Sq] 2021 May 21. Date of Electronic Publication: 2021 May 21.
Publication Year :
2021

Abstract

COVID-19 patients commonly present with neurological signs of central nervous system (CNS) <superscript>1-3</superscript> and/or peripheral nervous system dysfunction <superscript>4</superscript> . However, which neural cells are permissive to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been controversial. Here, we show that midbrain dopamine (DA) neurons derived from human pluripotent stem cells (hPSCs) are selectively permissive to SARS-CoV-2 infection both in vitro and upon transplantation in vivo , and that SARS-CoV-2 infection triggers a DA neuron inflammatory and cellular senescence response. A high-throughput screen in hPSC-derived DA neurons identified several FDA approved drugs, including riluzole, metformin, and imatinib, that can rescue the cellular senescence phenotype and prevent SARS-CoV-2 infection. RNA-seq analysis of human ventral midbrain tissue from COVID-19 patients, using formalin-fixed paraffin-embedded autopsy samples, confirmed the induction of an inflammatory and cellular senescence signature and identified low levels of SARS-CoV-2 transcripts. Our findings demonstrate that hPSC-derived DA neurons can serve as a disease model to study neuronal susceptibility to SARS-CoV-2 and to identify candidate neuroprotective drugs for COVID-19 patients. The susceptibility of hPSC-derived DA neurons to SARS-CoV-2 and the observed inflammatory and senescence transcriptional responses suggest the need for careful, long-term monitoring of neurological problems in COVID-19 patients.<br />Competing Interests: Competing Interests. R.E.S. is on the scientific advisory board of Miromatrix Inc and is a paid consultant and speaker for Alnylam Inc. L.S. is a scientific cofounder and paid consultant of BlueRock Therapeutics Inc. The other authors declare no competing interests.

Details

Language :
English
Database :
MEDLINE
Journal :
Research square
Accession number :
34031650
Full Text :
https://doi.org/10.21203/rs.3.rs-513461/v1